Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

Biomedtracker: follow the drug development process

Track and assess key events that will impact a drug’s probability of technical success and approval.

Key benefits:

Stay up to date
Get ahead of the competition
Conference coverage

View all content

Scrip

Five Trials To Look Out For At The AHA Meeting

By Alex Shimmings 13 Nov 2019

Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.

Topic Clinical trials Company analysis Research

View article
Scrip

Embracing China 2.0: AZ, Merck KGaA Set Up Funds, J&J Steps Up Digital Push

By Brian Yang 13 Nov 2019

AstraZeneca has pledged $1bn to a healthcare fund to support local innovation in China, joining big pharma peers J&J and Merck KGaA in fresh moves to embrace this market, where a new wave of digital technology transformation and fast-shifting trends now favor novel new therapies and the rise of local health start-ups.

Topic Digital Health

View article
Scrip

Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalise $3bn Deal

By Ian Haydock 06 Nov 2019

Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.

Topic Business strategies Deal trends

View article
Scrip

Amarin's Vascepa Momentum Builds Ahead Of Next Week's FDA AdComm

By Jessica Merrill 06 Nov 2019

Sales of the triglyceride-lowering medicine soared to $112.4m in the third quarter even before a label expansion that depends on the outcome of a vital US FDA advisory committee meeting on 14 November.

Topic Business strategies Company analysis

View article
Datamonitor Healthcare

Webinar: Outlook for NASH Therapies and Market Dynamics

By Joseph Haas 04 Nov 2019

Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.

Topic Cell and gene therapy Drug development landscape Drug approval

Full video
Scrip

Second Spring? Coverage Expansion Fuels Big Pharma China Growth But '4+7' Impact Lingers

By Brian Yang 01 Nov 2019

AstraZeneca, Novartis and Roche deliver north of 20% sales growth in China again, driven by expanded reimbursement coverage and new product launches, but some clouds are on the horizon over falling sales due to the impact of the expanding “4+7” centralized procurement scheme.

Topic Company analysis

View article
Scrip

Interview: AstraZeneca 'Is More Than Oncology'

By Sten Stovall 01 Nov 2019

Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this space.”

Topic Business strategies Drug development landscape

View article
Awareness, Datamonitor Healthcare

Post-ESMO Podcast 2019

31 Oct 2019

Listen to this podcast to keep up with the latest translational science and advancements in oncology to come out of the European Society of Medical Oncology (ESMO) Congress 2019. Datmonitor Healthcare’s post-event podcast delivers every important development.

Topic Cancer Research

Full podcast
Biomedtracker, Datamonitor Healthcare

2019 Post-ESMO Conference Report Extract

31 Oct 2019

Tap into insights and highlights from ESMO’s annual meeting of oncology clinicians, researchers, patient advocates, journalists, and members of the pharmaceutical industry.

Topic Cancer Drug development landscape Research

Single report
Datamonitor Healthcare

Insight into NASH Pricing Strategies

By Hannah Cohen 25 Oct 2019

Explore the key hurdles to anticipating the initial and potential value of the NASH therapy market.

Topic Drug approval Business strategies

View white paper
Trialtrove

Trialtrove's Patient-centric Trials Snapshot

24 Oct 2019

Review the trends, diseases, sponsors and outcomes involved with recent patient-centric clinical trials.

Topic Clinical trials

View infographic
Biomedtracker

Major Mergers & Acquisitions Highlights from Q1 2019

24 Oct 2019

Biomedtracker boils down all the important mergers and acquisitions activities in Q1.

Topic Business strategies Company analysis

View infographic
Trialtrove

Snapshot of the patient-centric trial landscape

24 Oct 2019

Patient-centric trials have been growing for years. Backed by data from Citeline’s Trialtrove, our latest infographic reveals the trends, the sponsors, and the impact on outcomes around Phase I, II, and III industry-sponsored, patient-centric trials.

Topic Drug development landscape

View infographic
Scrip

Interview: Why Europe's Biotech Prime Time Is Now

By Sten Stovall 23 Oct 2019

VC Firm Sofinnova’s Chair Papiernik Speaks After New Fund Launch The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.

Topic Business strategies Drug review

View article
Scrip

J&J's Spravato Set For EU Launches Soon

By Kevin Grogan 23 Oct 2019

Ketamine-Like Antidepressant Backed By CHMP If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the ﬁrst new mechanism of action in 30 years to treat major depressive disorder.

Topic Drug approval Drug development landscape

View article